256 related articles for article (PubMed ID: 32260340)
21. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.
Karihtala K; Leivonen SK; Karjalainen-Lindsberg ML; Chan FC; Steidl C; Pellinen T; Leppä S
Blood Adv; 2022 Mar; 6(6):1919-1931. PubMed ID: 34941990
[TBL] [Abstract][Full Text] [Related]
22. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of CD68
Troiano G; Caponio VCA; Adipietro I; Tepedino M; Santoro R; Laino L; Lo Russo L; Cirillo N; Lo Muzio L
Oral Oncol; 2019 Jun; 93():66-75. PubMed ID: 31109698
[TBL] [Abstract][Full Text] [Related]
24. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
25. Correlation of tumor-associated macrophage infiltration in glioblastoma with magnetic resonance imaging characteristics: a retrospective cross-sectional study.
Zhou Q; Xue C; Man J; Zhang P; Ke X; Zhao J; Zhang B; Zhou J
Quant Imaging Med Surg; 2023 Sep; 13(9):5958-5973. PubMed ID: 37711787
[TBL] [Abstract][Full Text] [Related]
26. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis.
Allison E; Edirimanne S; Matthews J; Fuller SJ
Oncol Ther; 2023 Mar; 11(1):27-48. PubMed ID: 36484945
[TBL] [Abstract][Full Text] [Related]
28. PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions.
Jiang LR; Zhang N; Chen ST; He J; Liu YH; Han YQ; Shi XQ; Yang JJ; Mu DY; Fu GH; Gao F
Front Oncol; 2021; 11():679928. PubMed ID: 34079767
[TBL] [Abstract][Full Text] [Related]
29. Programmed Cell Death Ligand 1 Expression in CD163 + Tumor-associated Macrophages in Cancer Gland Rupture Microenvironment.
Baş Y; Yilmaz B; Acar SF; Karadağ İ
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):176-182. PubMed ID: 38314768
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma.
Kim KJ; Wen XY; Yang HK; Kim WH; Kang GH
PLoS One; 2015; 10(12):e0144192. PubMed ID: 26714314
[TBL] [Abstract][Full Text] [Related]
31. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
32. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.
Klein JL; Nguyen TT; Bien-Willner GA; Chen L; Foyil KV; Bartlett NL; Duncavage EJ; Hassan A; Frater JL; Kreisel F
Am J Clin Pathol; 2014 Mar; 141(3):381-7. PubMed ID: 24515766
[TBL] [Abstract][Full Text] [Related]
33. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
Hwang I; Kim JW; Ylaya K; Chung EJ; Kitano H; Perry C; Hanaoka J; Fukuoka J; Chung JY; Hewitt SM
J Transl Med; 2020 Nov; 18(1):443. PubMed ID: 33228719
[TBL] [Abstract][Full Text] [Related]
34. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
35. Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma.
Kim YJ; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32756500
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK
Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma.
Zaki MA; Wada N; Ikeda J; Shibayama H; Hashimoto K; Yamagami T; Tatsumi Y; Tsukaguchi M; Take H; Tsudo M; Morii E; Aozasa K
Virchows Arch; 2011 Oct; 459(4):361-6. PubMed ID: 21874508
[TBL] [Abstract][Full Text] [Related]
38. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
